Dashboard
Manage Tickers

BMRN BIOMARIN PHARMACEUTICAL INC

Nasdaq biomarin.com


$ 53.29 $ -1.81 (-3.32 %)    

Monday, 27-Oct-2025 19:28:23 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 628.93 $ 10.99 (1.78 %)
DIA $ 475.40 $ 3.14 (0.66 %)
SPY $ 685.52 $ 7.99 (1.18 %)
TLT $ 91.88 $ 0.31 (0.34 %)
GLD $ 367.78 $ -10.51 (-2.78 %)
$ 52.67
$ 54.98
$ 52.01 x 1
$ 53.57 x 1
$ 52.26 - $ 55.84
$ 51.57 - $ 73.51
5,512,267
na
10.11B
$ 0.66
$ 15.39
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 05-02-2025 03-31-2025 10-Q
3 02-24-2025 12-31-2024 10-K
4 10-31-2024 09-30-2024 10-Q
5 08-05-2024 06-30-2024 10-Q
6 04-26-2024 03-31-2024 10-Q
7 02-26-2024 12-31-2023 10-K
8 11-02-2023 09-30-2023 10-Q
9 08-02-2023 06-30-2023 10-Q
10 04-28-2023 03-31-2023 10-Q
11 02-27-2023 12-31-2022 10-K
12 10-28-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 04-29-2022 03-31-2022 10-Q
15 02-25-2022 12-31-2021 10-K
16 10-29-2021 09-30-2021 10-Q
17 07-30-2021 06-30-2021 10-Q
18 04-30-2021 03-31-2021 10-Q
19 02-26-2021 12-31-2020 10-K
20 11-06-2020 09-30-2020 10-Q
21 08-05-2020 06-30-2020 10-Q
22 05-01-2020 03-31-2020 10-Q
23 02-27-2020 12-31-2019 10-K
24 10-29-2019 09-30-2019 10-Q
25 08-02-2019 06-30-2019 10-Q
26 04-29-2019 03-31-2019 10-Q
27 02-28-2019 12-31-2018 10-K
28 10-26-2018 09-30-2018 10-Q
29 08-03-2018 06-30-2018 10-Q
30 04-27-2018 03-31-2018 10-Q
31 02-26-2018 12-31-2017 10-K
32 10-31-2017 09-30-2017 10-Q
33 08-02-2017 06-30-2017 10-Q
34 05-04-2017 03-31-2017 10-Q
35 02-27-2017 12-31-2016 10-K
36 11-03-2016 09-30-2016 10-Q
37 08-08-2016 06-30-2016 10-Q
38 05-02-2016 03-31-2016 10-Q
39 02-29-2016 12-31-2015 10-K
40 11-02-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

biomarin-pharmaceutical-lowers-fy2025-adj-eps-guidance-from-440-455-to-350-360-vs-325-est-raises-fy2025-sales-guidance-from-3125b-3200b-to-3150b-3200b-vs-3171b-est
BioMarin Pharmaceutical Lowers FY2025 Adj ...
10/27/2025 20:07:18

BioMarin Pharmaceutical (NASDAQ:BMRN) lowers FY2025 Adj EPS guidance from $4.40-$4.55 to $3.50-$3.60 vs $3.25 analyst estimate....

biomarin-pharmaceutical-q3-adj-eps-012-misses-037-estimate-sales-776133m-miss-780629m-estimate
Biomarin Pharmaceutical Q3 Adj. EPS $0.12 ...
10/27/2025 20:05:24

Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly earnings of $0.12 per share which missed the analyst consensus estimat...

earnings-scheduled-for-october-27-2025
Earnings Scheduled For October 27, 2025
10/27/2025 08:32:18

Companies Reporting Before The Bell • Keurig Dr Pepper (NASDAQ:KDP) is projected to report quarterly earnings at $0.54 per sha...

what-to-expect-from-biomarin-pharmaceuticals-earnings
What to Expect from Biomarin Pharmaceutica...
10/24/2025 15:01:47

is-biomarin-pharmaceutical-inc-gaining-or-losing-market-support
Is BioMarin Pharmaceutical Inc Gaining or ...
10/09/2025 19:00:50

6-analysts-assess-biomarin-pharmaceutical-what-you-need-to-know
6 Analysts Assess BioMarin Pharmaceutical:...
10/09/2025 13:00:54

jp-morgan-maintains-overweight-on-biomarin-pharmaceutical-raises-price-target-to-119
JP Morgan Maintains Overweight on BioMarin...
10/09/2025 12:51:55

JP Morgan analyst Jessica Fye maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target ...

biomarin-pharmaceutical-expects-q3-will-include-acquired-iprd-charges-of-221m-on-a-pre-tax-basis-due-to-inozyme-pharma-deal-for-q3-co-expects-charge-of-about-110-to-both-gaap-and-non-gaap-eps-due-to-inozyme-pharma-deal
BioMarin Pharmaceutical Expects Q3 Will In...
10/07/2025 21:25:04

https://www.sec.gov/Archives/edgar/data/1048477/000104847725000101/bmrn-20251007.htm

peering-into-biomarin-pharmaceuticals-recent-short-interest
Peering Into BioMarin Pharmaceutical's Rec...
09/22/2025 20:00:45

ptc-therapeutics-could-challenge-biomarin-for-metabolic-disorder-treatment
PTC Therapeutics Could Challenge BioMarin ...
09/08/2025 17:56:24

BioMarin's Palynziq significantly lowered blood phenylalanine in teens with PKU, with nearly half reaching target levels in...

biomarin-pharmaceutical-presents-14-studies-at-american-society-for-bone-and-mineral-research-2025-annual-meeting-including-voxzogo-results
BioMarin Pharmaceutical Presents 14 Studie...
09/08/2025 13:07:22

forecasting-the-future-5-analyst-projections-for-biomarin-pharmaceutical
Forecasting The Future: 5 Analyst Projecti...
09/08/2025 12:00:52

this-duolingo-analyst-begins-coverage-on-a-bearish-note-here-are-top-5-initiations-for-monday
This Duolingo Analyst Begins Coverage On A...
09/08/2025 11:26:48

hc-wainwright--co-initiates-coverage-on-biomarin-pharmaceutical-with-neutral-rating-announces-price-target-of-60
HC Wainwright & Co. Initiates Coverage On ...
09/08/2025 11:05:07

HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on BioMarin Pharmaceutical (NASDAQ:BMRN) with a Neutra...

on-saturday-biomarin-pharmaceutical-announced-new-data-characterizing-the-efficacy-and-safety-of-palynziq-pegvaliase-pqpz-for-adolescents-with-phenylketonuria
On Saturday, BioMarin Pharmaceutical Annou...
09/07/2025 16:24:52

New data from Phase 3 PEGASUS study demonstrates a 49.7% decrease in mean blood Phe levels in adolescents aged 12-17 treated wi...

whats-driving-the-market-sentiment-around-biomarin-pharmaceutical
What's Driving the Market Sentiment Around...
08/29/2025 19:00:31

hedge-fund-elliott-managements-q2-moves-include-positions-tied-to-sp-500-nasdaq-nvidia-corrected
Hedge Fund Elliott Management's Q2 Moves I...
08/15/2025 19:42:50

Hedge fund Elliott Management revealed a Q2 portfolio reshuffle, adding new positions tied to major indexes and tech leaders li...

Core News & Articles
Elliott Investment Management L.P. Dissolv...
08/14/2025 21:49:47

- SEC Filing

is-biomarin-pharmaceutical-gaining-or-losing-market-support
Is BioMarin Pharmaceutical Gaining or Losi...
08/12/2025 20:00:35

guggenheim-maintains-buy-on-biomarin-pharmaceutical-raises-price-target-to-106
Guggenheim Maintains Buy on BioMarin Pharm...
08/06/2025 15:04:04

Guggenheim analyst Debjit Chattopadhyay maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy and raises the price targ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION